Kura Oncology Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics:

Net Product Revenue: $9.1 million from COMZIFTI sales, a significant increase from $0 in Q2 2025.

Collaboration Revenue: $11.8 million from the Kyowa Kirin partnership, down from $15.3 million in Q2 2025.

Research and Development Expenses: $61.9 million, slightly down from $62.8 million year-over-year.

Selling, General and Administrative Expenses: $31.8 million, up from $25.2 million in Q2 2025.

Net Loss: $68.3 million, compared to a net loss of $66.1 million in Q2 2025.

Cash Position: $519 million as of June 30, 2026, down from $667.2 million at the end of 2025.

2Strategic Updates and Business Highlights:

COMZIFTI Launch: Achieved a majority share of new patient starts in the relapsed/refractory NPM1-mutant AML menin inhibitor market within its second full quarter.

New Patient Metrics: 115 new patient starts and over 250 total prescriptions, indicating strong market penetration.

Combination Therapy Potential: Approximately 40% of new patient starts involved combination use with other therapies, suggesting a favorable physician response to COMZIFTI's profile.

Pipeline Development: Continued progress in clinical trials for Ziftomenib and darlifarnib, with multiple updates expected in the second half of the year.

3Forward Guidance and Outlook:

Collaboration Revenue Guidance: Expected to be $45 million to $55 million in 2026, $90 million to $110 million in 2027, and $90 million to $110 million in 2028.

Clinical Milestones: Anticipate multiple updates on clinical trials, including the pivotal KOMET-017 trial results expected in 2028.

4Challenges and Points of Concern:

Net Loss: The net loss increased year-over-year, raising concerns about ongoing cash burn.

Collaboration Revenue Decline: A decrease in collaboration revenue from Kyowa Kirin could indicate potential challenges in partnerships.

Competitive Pressures: Confusion exists in the market regarding competitive claims of new patient starts, with competitors also reporting significant shares, which may impact market dynamics.

5Notable Q&A Insights:

Market Dynamics: Management indicated that both market growth and share gains from competitors contributed to new patient starts, with ongoing efforts to maintain leadership.

Combination Use: The team emphasized the importance of combination therapies in driving future growth, with ongoing data generation to support this strategy.

Enrollment in KOMET-017: Enrollment is reportedly ahead of plan, attributed to the trial's convenient design and positive early data, which enhances physician interest.

Salesforce Experience: There are differences in prescription dynamics between sites familiar with Ziftomenib and those that are not, but overall engagement and growth are encouraging. This summary encapsulates Kura Oncology's performance and strategic direction as of Q2 2026, highlighting both achievements and areas of concern.